10:01 AM EST, 01/27/2025 (MT Newswires) -- Cartesian Therapeutics ( RNAC ) said Monday the US Food and Drug Administration has agreed to the design of its phase 3 AURORA trial for Descartes-08, its mRNA cell therapy for myasthenia gravis, a chronic autoimmune disorder that causes muscle weakness.

The company said the randomized trial, expected to begin in H1, will compare Descartes-08 to a placebo in about 100 participants with acetylcholine receptor autoantibody-positive myasthenia gravis.

The primary endpoint will measure the percentage of patients with a three-point or greater improvement in myasthenia gravis activities of daily living scores after four months, Cartesian added.

Shares of the company were up 2.9% in recent Monday trading.

Price: 19.76, Change: +0.56, Percent Change: +2.89